Join
Live feed
·
PRReleasevia Quantisnow
Armata Pharmaceuticals Inc. logo

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

ByQuantisnow·Wall Street's wire, on your screen.
ARMP· Armata Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARMP (Armata Pharmaceuticals Inc.) and more on Quantisnow.